Efficacy and Safety Study of Pembrolizumab (MK-3475) Versus Paclitaxel in Asian Participants With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-line Therapy With Platinum and Fluoropyrimidine (MK-3475-063/KEYNOTE-063)
Clinical trial NCT03019588 · TERMINATED
Trial details
- NCT number
- NCT03019588
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- TERMINATED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2017-02-16
- Primary completion
- 2021-06-29
- Enrollment
- 94
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.